Organovo(NASDAQ:ONVO) shares fell in response to a financing update yesterday: the company received a 15% hit to its stock price during NASDAQ trading. The California based 3D bioprinting company took a blow to their 3D printed kidneys after the market reacted unfavourably to news the company is seeking further investment.
根据向美国证券交易委员会（SEC）Organovo计划提交的文件，计划通过公开发行普通股来带来更多资金。
计划筹集2500万美元
Organovoexpect to raise approximately $25 million through the sale of 9 million shares at $2.75 per share. On Wednesday this week, prior to the end of day announcement, stock was trading at $3.50. When markets opened yesterday the price dropped to $2.85, a $0.65 decrease. In later trading Organovo recovered slightly to reach a close of $2.96.
券商Jefferies LLC和Evercore Group LLC)是handling the stock sale as joint book-running managers. Potential investors are invited to request a prospectus from either of these New York based firms.
Organovowill face questions from investors when it hosts an investment call to discuss Q2 earning early in November. The company were scheduled to make a preliminary earnings release earlier this month on October 11th according information from online finance resource, Daily Finance.
Long term Organovo investors must be experiencing something akin to a roller coaster ride. Since the company first went public in 2012 the share price has seen highs of $12.50 and lows of $1.56. Speculators have heralded the company as the next Apple and phrases such as, “一生的购买机会胡椒投资分析师概述。
生物技术投资的巨大奖励
However, biotech is a sector where historically only a small number of promising start-ups ever succeed in making good on early promise. But for those few who manage to overcome technical and regulatory hurdles and commercialise their IP, the rewards can be spectacular.
Organovo’s3D printed liver and kidney assay products已获得目标市场的热烈接待：在将新药推向市场时，希望最大程度地降低风险的制药公司。该公司的3D印刷皮肤产品还具有收入来源，其中一位客户是化妆品公司L'Oreal声明this product will reduce the need for animal testing。
如此崇高的野心需要时间和金钱，对于专注于短期绩效的投资者来说，这些野心似乎已经用完了。但是，对于那些对3D生物打印或再生医学背后的科学应用更感兴趣的人来说，股价远非有用的指标。
